PHASE II STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) IN RELAPSED NSCLC

辛二酰苯胺羟肟酸 (SAHA) 在复发 NSCLC 中的 II 期研究

• 批准号: 7607543
• 负责人: ANNE M TRAYNOR
• 金额: $ 0.01万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607543
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Drug usage; Enzymes; Funding; Grant; Growth; Institution; Non-Small-Cell Lung Carcinoma; Patients; Phase; Phase II Clinical Trials; Recurrence; Relapse; Research; Research Personnel; Resources; Source; Staging; United States National Institutes of Health; Vorinostat; Work; cell growth; cell killing; chemotherapy; neoplastic cell

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This Phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 (from ClinicalTrials.gov网站） 用于化疗的药物，如辛二酰苯胺异羟肟酸，以不同的方式阻止肿瘤细胞的生长，要么通过杀死细胞，要么通过阻止它们分裂。辛二酰苯胺异羟肟酸也可以通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。 这项II期试验正在研究辛二酰苯胺异羟肟酸在治疗IIIB期、IV期或复发性非小细胞肺癌患者中的作用。